Upstream Bio, Inc. (UPB) stock
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.78−0.08 (-2.80%)
Close on Nov 13, 2026Market cap $152.26MP/E –Yield –
Upstream Bio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Upstream Bio's ebitda for the twelve months ending Sep 30, 2026 was -$175.32M. For fiscal 2025 it was -$160.17M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$160.17M | – |
| FY2024 | Dec 31, 2024 | -$77.68M | – |
| FY2023 | Dec 31, 2023 | -$40.05M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$43.33M | – |
| Q2 FY2026 | Jun 30, 2026 | -$42.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$43.57M | – |
| Q4 FY2025 | Dec 31, 2025 | -$46.11M | – |
| Q3 FY2025 | Sep 30, 2025 | -$37.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.31M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.97M | – |
| Q4 FY2024 | Dec 31, 2024 | -$26.27M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.88M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.00M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.32M | – |
See a number that looks wrong?